Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer
2020 ASCO-SITC Clinical Immuno-Oncology SymposiumDario Vignali, PhD, of the University of Pittsburgh and UPMC Hillman Cancer Center, summarizes his Keynote Address, which covered what drives systemic immune dysfunction in patients with cancer, what promotes inhibitory receptor expression, and what limits the persistence of antigen-specific T cells.
Related Videos
Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes
Christopher B. Cole, MD, PhD, of the National Cancer Institute, discusses findings from a phase I study of intraperitoneal monocytes activated by interferons alpha and gamma ...
John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy
John N. Lukens, MD, of the Hospital of the University of Pennsylvania, discusses his finding that taking antibiotics within 3 months of starting treatment with immune checkpo...
Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D
Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy c...
Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year
Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for thi...
Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights
Jacob J. Adashek, DO, of the University of South Florida and Moffitt Cancer Center, discusses data on combining immunoregulatory inhibition and targeted gene therapy, which m...
